RxDoctor Payments Data

Keith Junior, MD

Internal Medicine · Nashville, TNNPI 1811911449

Payments from drug & device makers

$696in general payments, 2019–2025

Across 36 payments — averaging $19.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$104
  • AstraZeneca$97
  • Alkermes, Inc.$92
  • Hologic Sales And Service, LLC$53
  • Gilead$45
  • Exact Sciences$43
  • plus $261 from 10 others

What the payments were for

  • Food & beverage$696100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK6$104
AstraZeneca6$97
Alkermes, Inc.4$92
Hologic Sales And Service, LLC2$53
Gilead2$45
Exact Sciences3$43
Novo Nordisk2$41
Amgen1$31
Lilly USA, LLC2$29
Abbott1$28
Bayer2$26
Insulet Corporation1$25
AbbVie1$25
VBI Vaccine (delaware) Inc.1$22
Medtronic1$17
Pfizer1$16

How this compares

$696 in reported general payments places this provider in the 60th percentile of 2,216 internal medicine providers in Tennessee.

See all internal medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$865
Medicare patients
32
Services billed
98

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol59$46,903
TrulicityDulaglutide33$44,387
EliquisApixaban50$31,744
JardianceEmpagliflozin28$19,210
JanuviaSitagliptin Phosphate20$17,589
OzempicSemaglutide16$17,094
XareltoRivaroxaban14$12,581
Bydureon BciseExenatide Microspheres12$11,518
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$7,507
Lantus SolostarInsulin Glargine,hum.Rec.Anlog49$4,986
Atorvastatin Calcium430$3,830
Albuterol Sulfate HfaAlbuterol Sulfate177$3,756
Insulin Lispro Kwikpen U-100Insulin Lispro17$3,441
Celecoxib33$3,009
Fluticasone-SalmeterolFluticasone Propion/Salmeterol11$2,380

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere$97$54,41070 claims
Lilly USA, LLCTrulicity$29$44,38733 claims
PfizerEliquis$16$31,74450 claims
Novo NordiskOzempic$41$17,09416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,216 internal medicine providers in Tennessee.

Other internal medicine in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →